Sugi Predict

Sugi Predict / Targets / GLS2

GLS2

Glutaminase liver isoform, mitochondrial · Q9UI32 · GLS2 on Sugi Atlas →

1,808 patent compounds predicted against GLS2, 671 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13846877 SCHEMBL13846877 0.87 6/20
SCHEMBL13846859 SCHEMBL13846859 0.67 6/20
SCHEMBL13846866 SCHEMBL13846866 0.78 5/20
SCHEMBL18545405 SCHEMBL18545405 0.78 5/20
SCHEMBL1250446 SCHEMBL1250446 0.58 5/20
SCHEMBL1250448 SCHEMBL1250448 0.58 5/20
SCHEMBL12891998 SCHEMBL12891998 0.58 5/20
SCHEMBL1250012 SCHEMBL1250012 0.53 5/20
SCHEMBL1250013 SCHEMBL1250013 0.53 5/20
SCHEMBL14381927 SCHEMBL14381927 0.52 5/20
SCHEMBL1249980 SCHEMBL1249980 0.73 4/20
SCHEMBL1249981 SCHEMBL1249981 0.73 4/20
SCHEMBL12892002 SCHEMBL12892002 0.73 4/20
SCHEMBL12009058 SCHEMBL12009058 0.66 4/20
SCHEMBL18545484 SCHEMBL18545484 0.66 4/20
SCHEMBL13846851 SCHEMBL13846851 0.62 4/20
SCHEMBL13464571 SCHEMBL13464571 0.51 4/20
SCHEMBL1250010 SCHEMBL1250010 0.49 4/20
SCHEMBL1250011 SCHEMBL1250011 0.49 4/20
SCHEMBL5827658 SCHEMBL5827658 0.47 4/20

Clinical trials — most relevant to GLS2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment PHASE4COMPLETED
Paracetamol Study in Patients With Low Muscle Mass PHASE4UNKNOWN
Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy PHASE3COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure PHASE2UNKNOWN
Resveratrol and Human Hepatocyte Function in Cancer PHASE1/PHASE2WITHDRAWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Serine Supplementation for Obese Subjects With Fatty Liver Disease PHASE1/PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
The KHENERGY Study PHASE2COMPLETED
Predicts Mortality by AST/ALT Ration in Patients with Sepsis and Septic Shock During ICU Admissin nanNOT_YET_RECRUITING
Relation of White Blood Cell Function to Diabetes nanCOMPLETED
Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting. nanNOT_YET_RECRUITING
Assessment of Microorganisms and Host Response In Liver Diseases nanNOT_YET_RECRUITING
Metabolic Determinants of Cardiac Function nanCOMPLETED
Echocardiographic Findings as Markers of Subclinical Cardiac Dysfunction in Patients With Non-Alcoholic Fatty Liver Disease nanUNKNOWN
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases nanCOMPLETED
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors nanRECRUITING
Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS nanCOMPLETED
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Hepatic Energy Fluxes in NASH and NAS Patients nanACTIVE_NOT_RECRUITING
Development of Novel Therapies for NIDDM nanCOMPLETED
Effect of Nutritional Supplementation and Pulmonary Rehabilitation on the Clinical Status of HF and COPD nanUNKNOWN
Hepatic Substrate Flux Rates in Type 2 Diabetes nanACTIVE_NOT_RECRUITING
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome nanCOMPLETED
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging nanCOMPLETED
Lifestyle Intervention in Fatty Liver (NAFLD) nanUNKNOWN
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a GLS2 binder may also engage these)

ProteinNameSimilarity
P28492 — 1.000 P28492 →
Q571F8 — 0.995 Q571F8 →
Q9SMX1 — 0.969 Q9SMX1 →
Q64323 — 0.967 Q64323 →
E9Q4Z2 — 0.966 E9Q4Z2 →
Q9FN41 — 0.966 Q9FN41 →
B4G0F3 — 0.965 B4G0F3 →
ME3 NADP-dependent malic enzyme, mitochondrial 0.964 landscape →
Q4V7N2 — 0.964 Q4V7N2 →
Q8IYB8 — 0.964 Q8IYB8 →
Q5ZKY2 — 0.964 Q5ZKY2 →
Q8BMF3 — 0.964 Q8BMF3 →
A0FKG7 — 0.963 A0FKG7 →
Q9ER88 — 0.963 Q9ER88 →
Q5BJZ6 — 0.962 Q5BJZ6 →
P26443 — 0.962 P26443 →
Q7ZWS1 — 0.962 Q7ZWS1 →
Q2R483 — 0.962 Q2R483 →
UBA3 NEDD8-activating enzyme E1 catalytic subunit 0.962 landscape →
P42174 — 0.962 P42174 →
A0A7U2QYM2 — 0.962 A0A7U2QYM2 →
Q04499 — 0.961 Q04499 →
Q5RFI8 — 0.961 Q5RFI8 →
F4JJJ3 — 0.961 F4JJJ3 →
ACACB Acetyl-CoA carboxylase 2 0.961 landscape →
Q6NYL5 — 0.961 Q6NYL5 →
E0CTF3 — 0.961 E0CTF3 →
Q64I00 — 0.961 Q64I00 →
Q9WU79 — 0.961 Q9WU79 →
Q91ZS8 — 0.961 Q91ZS8 →